Group 1 - The core viewpoint of the articles highlights the significant financial improvement of the company, with a net loss of 94.631 million yuan in 2024, a reduction of 90.8% year-on-year [1] - The company's revenue reached approximately 9.422 billion yuan, representing a year-on-year growth of 51.8%, while gross profit was about 7.912 billion yuan, up 56.1% year-on-year [1] - Product revenue amounted to 8.228 billion yuan, showing a year-on-year increase of 43.6%, driven by strong performance in the oncology sector and the rapid launch of new products [1] Group 2 - The company achieved a milestone by turning positive in both Non-IFRS profit and EBITDA for the first time in 2024, reflecting strong revenue growth and successful R&D progress [2] - As of December 31, 2024, the company held approximately 10.22 billion yuan (over 1.4 billion USD) in cash and financial assets, providing solid financial support for long-term strategic goals [2] - The commercial product portfolio expanded to 15 products, with five new drugs approved, including three targeted therapies for lung cancer and the first non-covalent BTK inhibitor for hematological malignancies in China [2]
信达生物(01801)公布2024年业绩 净亏损9463.1万元 同比收窄90.8%